NYSEMKT: RGNTRegentis Biomaterials Ltd Stock
$3.36+0.01 (+0.3%)
Updated Mar 6, 2026
RGNT Price
$3.36
Fair Value Price
N/A
Market Cap
$17.40M
52 Week Low
$3.10
52 Week High
$8.35
P/E
-0.14x
P/B
3.67x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.61
Operating Cash Flow
-$1M
Beta
1.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RGNT's potential to beat the market
- RGNT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
RGNT
RankedUnranked of 43
RankedUnranked of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.48 | A | |
| $9.07 | A | |
| $26.86 | A |
Be the first to know about important RGNT news, forecast changes, insider trades & much more!
RGNT News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RGNT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RGNT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RGNT is poor value based on its book value relative to its share price (3.67x), compared to the US Medical Instruments & Supplies industry average (3.57x)
P/B vs Industry Valuation
RGNT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RGNT due diligence checks available for Premium users.
Valuation
RGNT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.14x
Industry
-438.87x
Market
37.34x
RGNT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.67x
Industry
3.57x
RGNT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RGNT's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
RGNT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.6M
Liabilities
$2.9M
Debt to equity
0.61
RGNT's short-term assets ($7.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RGNT's short-term assets ($7.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RGNT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
RGNT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RGNT vs Medical Stocks
Regentis Biomaterials Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.